Asembia LLC, an industry leader in specialty pharmacy management company, recently unveiled its new HUB service and patient support program, which was developed as part of a partnership with MannKind Corp. and is designed for Afrezza Inhalation Powder.
Afrezza Inhalation Powder is a fast-acting insulin that is inhaled for the treatment of adults with diabetes to help them control their high blood sugar.
"We look forward to working with MannKind to support their patients' needs and help them navigate reimbursement challenges and product access for their prescriptions," Asembia CEO Lawrence Irene said. "As our HUB services and technology capabilities at Asembia continue to expand, our organization is well-positioned to support brands which require a high-touch approach to ensure optimized patient care and access."
The new HUB service from Asembia features end-to-end product support as well as a web-based prescriber portal that will use the newest technology.
"Utilizing Asembia's comprehensive HUB Services will ensure a white-glove patient experience, and support services that increase patient retention during the first three months of treatment and ensure we streamline the prescription process for physicians and patients who are prescribed Afrezza,” MannKind Chief Commercial Officer Michael Castagna said.
Alerts Sign-up